nūhou

ʻOiai ʻo Iniparib ka pā uʻi paʻa maikaʻi o ka nele, ua hoʻi ka PARP inhibitors i ka ʻaka o ka umauma pale ma hope o ka haki ʻana i ka pale maʻi ovarian, me Olaparib a me Talazoparib e kūleʻa ana i ka lāʻau lapaʻau lāʻau-hoʻokahi no nā poʻe maʻi me ka maʻi metastatic holomua [2-3].

Eia nō naʻe, i ka umauma maʻi umauma, mālama ʻia ka pale o PARP e hakakā i ka nui o ka maʻi pulima o ka maʻi lolo nui ka trethal, ʻo ia ka subtype o nā maʻi me ka hemahema o BRCA1. ʻOiai hiki ke loaʻa ka mālama ʻana o nā lāʻau lapaʻau hoʻokahi, ʻo ke kūlana i hoʻonui ʻia? Ma hope o ka hoʻouka ʻana, hiki paha iā ʻoe ke koho maikaʻi loa ma ka papahana lāʻau.

Hōʻike ʻo Niraparib, he hōkū wīwī o ka papa o nā PARP, i kēia mau hopena.Preliminary o nā hopena mai ka hopena o ka hoʻokolokolo TOPACIO / KEYNOTE 162 ua hōʻike ʻo Niraparib i hui pū me Pembrozulimab (K) i pane mai i ka pae pane pane ʻana o 29% i nā mea maʻi me ka maʻi maʻi umauma triple-negatif. a ʻaʻole i kaupalena ʻia i nā mea maʻi me nā gen brca1 / 2.

Hōʻike ʻia ka hopena o nā ʻano lāʻau lapaʻau like ʻole i ka hopena o nā lāʻau like ʻole ma ka ʻike loea i ka hakakā ʻana i ka hakakā ʻana i ka umauma maʻi. No ka mea like, ʻo Talazoparib a me Veliparib i kūleʻa a kūleʻa ʻole ma kahi like ʻole neoadjuvant therapy [5]. No laila, ma ka mālama ʻana i nā maʻi umauma o ka umauma, ʻo ka ʻakaʻaka hope loa, he ʻakaʻaka maikaʻi loa.
ʻO kaʻoiaʻiʻo, ʻaʻole pono nā mea hoʻokele PARP e loaʻa i nā wahine wale nō, akā ʻo ka kaulike wahine.


Nā hola mālama: Mei-28-2020